These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25700292)

  • 1. The nature of placebo response in clinical studies of major depressive disorder.
    Papakostas GI; Østergaard SD; Iovieno N
    J Clin Psychiatry; 2015 Apr; 76(4):456-66. PubMed ID: 25700292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
    Papakostas GI; Martinson MA; Fava M; Iovieno N
    J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma.
    Gispen-de Wied C; Stoyanova V; Yu Y; Isaac M; Pani L; de Andres-Trelles F
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):804-11. PubMed ID: 22704716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.
    Kobak KA; Leuchter A; DeBrota D; Engelhardt N; Williams JB; Cook IA; Leon AC; Alpert J
    J Clin Psychopharmacol; 2010 Apr; 30(2):193-7. PubMed ID: 20520295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.
    Bridge JA; Birmaher B; Iyengar S; Barbe RP; Brent DA
    Am J Psychiatry; 2009 Jan; 166(1):42-9. PubMed ID: 19047322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews.
    Khan A; Faucett J; Brown WA
    J Psychiatr Res; 2014 Apr; 51():88-92. PubMed ID: 24477068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major depression: the importance of clinical characteristics and treatment response to prognosis.
    Katon W; Unützer J; Russo J
    Depress Anxiety; 2010; 27(1):19-26. PubMed ID: 19798766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
    Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
    Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.
    Targum SD; Wedel PC; Robinson J; Daniel DG; Busner J; Bleicher LS; Rauh P; Barlow C
    J Psychiatr Res; 2013 Jul; 47(7):944-54. PubMed ID: 23562150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.